Glabellar Lines: Clinical Trials

22 trials for Glabellar Lines, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

22 completed. 22 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 322Completed 22

Follow Glabellar Lines: new trials by email Literature Review of Glabellar Lines trials Research Report on Glabellar Lines

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines
Abobotulinumtoxin A (Espad Pharmed Darou Co.), Abobotulinumtoxin A (Ipsen Co.) - Glabellar Lines, Glabellar Frown Lines
Phase 3CompletedEspad Pharmed1462024-05-282025-05-07
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
AGN-151586, Placebo - Glabellar Lines
Phase 3CompletedAbbVie1612024-03-292026-06-26
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
CKDB-501A, Botox® - Glabellar Lines
Phase 3CompletedCKD Bio Corporation3002023-04-132023-12-12
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Placebo, AGN-151586 - Glabellar Lines
Phase 3CompletedAbbVie6382022-03-162024-05-24
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
AGN-151586, Placebo - Glabellar Lines
Phase 3CompletedAbbVie3092022-03-082026-02-18
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
AGN-151586 - Glabellar Lines
Phase 3CompletedAbbVie9922022-02-252026-09-25
Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.
Botulinum Toxin Type A Injection [INI101], Botulinum Toxin Type A Injection [Botox] - Glabellar Lines
Phase 3CompletedINIBIO Co., Ltd.2922021-05-272026-06-03
Treatment of Moderate to Severe Glabellar Lines (BMI2006)
BMI2006, BOTOX® - Glabellar Lines
Phase 3CompletedBMI Korea2782021-02-092022-09-08
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
botulinum toxin neuromodulator - Glabellar Lines, Lateral Canthal Lines
Phase 3CompletedGalderma R&D9022020-01-272023-06-18
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
MT10109L Dose 1, MT10109L Dose 2, MT10109L Dose 1 + Dose 2 - Glabellar Lines, Lateral Canthal Lines
Phase 3CompletedMedy-Tox9572019-10-232024-08-09
MT10109L in the Treatment of Glabellar Lines
MT10109L, Placebo - Glabellar Lines
Phase 3CompletedMedy-Tox2342018-12-242023-07-27
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
MT10109L, Placebo - Lateral Canthal Lines, Glabellar Lines
Phase 3CompletedMedy-Tox4252018-11-052023-07-17
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
MT10109L, Placebo - Glabellar Lines, Lateral Canthal Lines
Phase 3CompletedMedy-Tox4152018-10-262023-05-25
Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.
Botulinum Toxin A type for injection (Botulax®), Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®) - Glabellar Lines
Phase 3CompletedHugel5002017-05-092022-05-24
Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines
Neuronox, Botox - Glabellar Lines
Phase 3CompletedMedy-Tox5042016-03-302017-07-13
Dysport in the Treatment of Glabellar Lines in Chinese Subjects
Botulinum toxin type A, Placebo - Glabellar Lines
Phase 3CompletedIpsen5202015-04-012019-08-06
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
Botulinum toxin type A, Placebo - Glabellar Lines
Phase 3CompletedIpsen6002015-04-012022-09-28
BOTOX® in the Treatment of Upper Facial Lines in Japan
botulinum toxin Type A (44U), botulinum toxin Type A (32U) - Upper Facial Rhytides, Crow's Feet Lines
Phase 3CompletedAllergan1012013-02-012015-02-10
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U - Facial Rhytides, Crow's Feet Lines
Phase 3CompletedAllergan6842011-05-012014-02-25
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
onabotulinumtoxinA 24 U, onabotulinumtoxinA 44 U, normal saline - Facial Rhytides, Crow's Feet Lines
Phase 3CompletedAllergan9172010-09-012019-04-16

Showing 20 of 22. Sign in to see all of them.

Interventions

Botulinum Toxins, Type A (12)  ·  Saline Solution (2)  ·  abobotulinumtoxinA (2)  ·  Injections (1)  ·  Sodium Chloride (1)  ·  incobotulinumtoxinA (1)

Sponsors

Medy-Tox (5)  ·  AbbVie (4)  ·  Allergan (3)  ·  Ipsen (2)  ·  BMI Korea (1)  ·  CKD Bio Corporation (1)  ·  Espad Pharmed (1)  ·  Galderma R&D (1)  ·  GlaxoSmithKline (1)  ·  Hugel (1)  ·  INIBIO Co., Ltd. (1)  ·  Merz Pharmaceuticals GmbH (1)

Countries

United States (11)  ·  Canada (8)  ·  Germany (8)  ·  South Korea (4)  ·  China (3)  ·  France (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Japan (2)  ·  Puerto Rico (2)  ·  Russia (2)  ·  Hungary (1)  ·  Iran (1)  ·  Poland (1)  ·  Taiwan (1)

Top investigators

SangMi Park (4)  ·  Alireza Firooz, Medical Doctor (1)  ·  Beom Joon Kim, MD, Ph.D. (1)  ·  Beomjoon Kim (1)  ·  Berthold Rzany, Prof. Dr. med Sc.M. (1)  ·  Timothy Corcoran Flynn, MD (1)

Results publications

PMID 23190342, PMID 36206385, PMID 40586136

NIH funding

2014 (4), 2018 (1)